Literature DB >> 2223648

Natural history of stage A chronic lymphocytic leukaemia untreated patients. French Cooperative Group on Chronic Lymphocytic Leukaemia.

.   

Abstract

In chronic lymphocytic leukaemia (CLL), stage A was defined in 1979 as the best prognostic group of the three-stage (A, B, C) classification which was thereafter adopted by an International Workshop on CLL. Recently, the question of whether or not all stage A patients should be treated was raised by authors who described potential harmful effects of treatment among stage A patients and heterogeneity of stage A with respect to survival and disease progression. In this work, we studied the natural history of stage A-CLL in order to determine on which grounds a decision to treat should be made. We performed a prognostic study on 309 untreated stage A-CLL patients enrolled in a randomized clinical trial from 1980 to 1985. Our aim was to segregate a subgroup with a low probability of disease progression and death. We used three endpoints: overall survival (50 deaths), disease progression to stage B or C (78 events) and disease progression to stage C (39 events). Multivariate analyses, using Cox's model, selected nine variables as having a prognostic value for at least one endpoint, namely age, sex, general symptoms, involved axillary lymph node, splenomegaly, haemoglobin, platelets, lymphocyte count and bone-marrow infiltration. By considering the three endpoints jointly, we obtained a proposed definition of smouldering CLL based on four variables, namely haemoglobin level, lymphocyte count, the number of enlarged areas and bone-marrow infiltration. However, we did not succeed in better defining smouldering CLL than in a previous proposal, based on haemoglobin level and lymphocyte count. Moreover, whatever the definition used, including other previous works, disease progression within 5 years was still observed for about 10% of patients with smouldering CLL. Future attempts to define smouldering CLL could perhaps benefit from using biological markers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223648     DOI: 10.1111/j.1365-2141.1990.tb07835.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

Review 1.  New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.

Authors:  Folke Schriever; Dieter Huhn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Giulia Fabbri; Valeria Spina; Marco Fangazio; Francesco Forconi; Roberto Marasca; Luca Laurenti; Alessio Bruscaggin; Michaela Cerri; Sara Monti; Stefania Cresta; Rosella Famà; Lorenzo De Paoli; Pietro Bulian; Valter Gattei; Anna Guarini; Silvia Deaglio; Daniela Capello; Raul Rabadan; Laura Pasqualucci; Riccardo Dalla-Favera; Robin Foà; Gianluca Gaidano
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

3.  White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Francesca Romana Mauro; Maria Stefania De Propris; Simona Santangelo; Marilisa Marinelli; Nadia Peragine; Valeria Di Maio; Mauro Nanni; Rita Barzotti; Francesca Mancini; Daniele Armiento; Francesca Paoloni; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

4.  A population-based assessment of the prognostic value of the CD19 positive lymphocyte count in B-cell chronic lymphocytic leukemia using Cox and Markov models.

Authors:  R Cailliod; C Quantin; P M Carli; V Jooste; G Le Teuff; C Binquet; M Maynadie
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

5.  B-cell clones as early markers for chronic lymphocytic leukemia.

Authors:  Ola Landgren; Maher Albitar; Wanlong Ma; Fatima Abbasi; Richard B Hayes; Paolo Ghia; Gerald E Marti; Neil E Caporaso
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

Review 6.  Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 7.  Monoclonal B cell lymphocytosis--what does it really mean?

Authors:  Andy C Rawstron
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 8.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 9.  Personalized medicine in CLL: current status and future perspectives.

Authors:  Uri Rozovski; Inbal Hazan-Halevy; Michael J Keating; Zeev Estrov
Journal:  Cancer Lett       Date:  2013-07-20       Impact factor: 8.679

10.  A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders.

Authors:  S P Sah; E Matutes; A C Wotherspoon; R Morilla; D Catovsky
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.